Showing results (1-10 of 117) with videos related to
Sort By:
Pageof 12
International Journal of Cancer|September 25, 2024
The future of immunotherapy for diffuse large B-cell lymphomaJohannes Duell, Jason WestinJournal of Comparative Effectiveness Research|November 19, 2013
R-CHOP every 21 days for diffuse large B-cell lymphoma: still the standard of care?Jason Westin, Fredrick HagemeisterCurrent Oncology Reports|October 20, 2023
Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell LymphomaAnath C Lionel, Jason WestinBlood|March 3, 2022
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?Jason Westin, Laurie H SehnLeukemia & Lymphoma|January 6, 2021
Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphomaHua-Jay J Cherng, Jason WestinAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 10, 2025
Speaking to Power With Power: Advocating for Your ProfessionMartin Palmeri, Eric J McNulty, Alti Rahman, et al.Bone Marrow Transplantation|August 22, 2019
The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCTHermann Einsele, Leo Rasche, Max S Topp, et al.Cancer Journal (Sudbury, Mass.)|September 26, 2025
The Oncology Drug Shortage: ASCO's Vision and Proposals for Resolving This Public Health EmergencyJason Westin, Dominic Sawaya, Shimere Williams Sherwood, et al.Pageof 12